Patient-, donor-, disease-, and transplant-related factors in 102 children who underwent haploHSCT for ALL in remission, according to number of transplantations performed during the study period
| . | Fewer than 231 alloHSCTs performed . | 231 or more alloHSCTs performed . | P . |
|---|---|---|---|
| Patient-related factors | |||
| Age, y | 8.8 (0.96-16) | 8.7 (0.64-15.7) | .64 |
| Sex | |||
| Male | 32 | 38 | .63 |
| Female (%) | 13 (29) | 19 (33) | |
| CMV serology | |||
| Negative | 8 | 32 | < .001* |
| Positive (%) | 35 (81) | 24 (43) | |
| Donor-related factors | |||
| Age, y | 36 (18.6-49.5) | 36.9 (18-53.8) | .8 |
| Sex | |||
| Male | 20 | 35 | .09 |
| Female (%) | 25 (56) | 22 (39) | |
| CMV serology | |||
| Negative | 8 | 24 | .02* |
| Positive (%) | 30 (79) | 31 (56) | |
| Disease-related factors | |||
| WBC at diagnosis | 21.25 (2.8-517) | 27.9 (1.9-272.4) | .67 |
| Cytogenetics | |||
| No Ph+ | 27 | 36 | .25 |
| Ph+ or t(4;11) (%) | 7 (21) | 17 (32) | |
| Previous autologous transplantation | |||
| No | 39 | 55 | .07 |
| Yes (%) | 6 (13) | 2 (4) | |
| Status at transplantation (%) | |||
| CR1 | 6 (13) | 16 (28) | .2 |
| CR2 | 23 (51) | 25 (44) | |
| CR3 | 16 (36) | 16 (28) | |
| Transplant-related factors | |||
| Year of transplantation | 2000 (1995-2004) | 2000 (1995-2004) | .8 |
| No. of antigen mismatch in HLA-A, -B, -DR | |||
| 2 | 17 | 17 | .31 |
| 3 (%) | 28 (62) | 40 (70) | |
| Female donor to male recipient | |||
| No | 28 | 43 | .15 |
| Yes (%) | 17 (38) | 14 (25) | |
| Cell source | |||
| BM | 3 | 3 | .77 |
| PB (%) | 42 (93) | 54 (95) | |
| Type of T-cell depletion (%) | |||
| CliniMacs | 30 (68) | 48 (84) | .04* |
| Isolex | 9 (21) | 3 (5) | |
| Cellpro | 4 (9) | 2 (4) | |
| Negative T-depletion | 1 (2) | 4 (7) | |
| No. of CD34+ cells infused ×106/kg body weight | 12.7 (1.36-95.2) | 12.1 (3-33) | .68 |
| TBI in conditioning | |||
| No | 16 | 8 | .01* |
| Yes (%) | 29 (64) | 49 (86) | |
| ATG/ALG in conditioning | |||
| No | 4 | 18 | .01* |
| Yes (%) | 38 (90) | 38 (68) |
| . | Fewer than 231 alloHSCTs performed . | 231 or more alloHSCTs performed . | P . |
|---|---|---|---|
| Patient-related factors | |||
| Age, y | 8.8 (0.96-16) | 8.7 (0.64-15.7) | .64 |
| Sex | |||
| Male | 32 | 38 | .63 |
| Female (%) | 13 (29) | 19 (33) | |
| CMV serology | |||
| Negative | 8 | 32 | < .001* |
| Positive (%) | 35 (81) | 24 (43) | |
| Donor-related factors | |||
| Age, y | 36 (18.6-49.5) | 36.9 (18-53.8) | .8 |
| Sex | |||
| Male | 20 | 35 | .09 |
| Female (%) | 25 (56) | 22 (39) | |
| CMV serology | |||
| Negative | 8 | 24 | .02* |
| Positive (%) | 30 (79) | 31 (56) | |
| Disease-related factors | |||
| WBC at diagnosis | 21.25 (2.8-517) | 27.9 (1.9-272.4) | .67 |
| Cytogenetics | |||
| No Ph+ | 27 | 36 | .25 |
| Ph+ or t(4;11) (%) | 7 (21) | 17 (32) | |
| Previous autologous transplantation | |||
| No | 39 | 55 | .07 |
| Yes (%) | 6 (13) | 2 (4) | |
| Status at transplantation (%) | |||
| CR1 | 6 (13) | 16 (28) | .2 |
| CR2 | 23 (51) | 25 (44) | |
| CR3 | 16 (36) | 16 (28) | |
| Transplant-related factors | |||
| Year of transplantation | 2000 (1995-2004) | 2000 (1995-2004) | .8 |
| No. of antigen mismatch in HLA-A, -B, -DR | |||
| 2 | 17 | 17 | .31 |
| 3 (%) | 28 (62) | 40 (70) | |
| Female donor to male recipient | |||
| No | 28 | 43 | .15 |
| Yes (%) | 17 (38) | 14 (25) | |
| Cell source | |||
| BM | 3 | 3 | .77 |
| PB (%) | 42 (93) | 54 (95) | |
| Type of T-cell depletion (%) | |||
| CliniMacs | 30 (68) | 48 (84) | .04* |
| Isolex | 9 (21) | 3 (5) | |
| Cellpro | 4 (9) | 2 (4) | |
| Negative T-depletion | 1 (2) | 4 (7) | |
| No. of CD34+ cells infused ×106/kg body weight | 12.7 (1.36-95.2) | 12.1 (3-33) | .68 |
| TBI in conditioning | |||
| No | 16 | 8 | .01* |
| Yes (%) | 29 (64) | 49 (86) | |
| ATG/ALG in conditioning | |||
| No | 4 | 18 | .01* |
| Yes (%) | 38 (90) | 38 (68) |
CMV indicates cytomegalovirus; WBC, white blood cell count; Ph+, Philadelphia chromosome–positive; CR, complete remission; BM, bone marrow; PB, peripheral blood; TBI, total body irradiation; ATG, antithymocyte globulin; and ALG, antilymphocyte globulin.
Statistically significant.